Clinical Trial Update: Coronary Vasomotor Response After Riociguat Exposure [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating coronary vasomotor response after riociguat exposure has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• Riociguat (riociguat)

Snippet

Sponsor: Bayer | Conditions: Coronary Artery Disease | Phase 2 | Status: WITHDRAWN